Boenning & Scattergood Initiates Coverage on Insulet (PODD) with an Outperform
More News related to PODD
- Insulet Corporation to Present at the Piper Jaffray Health Care Conference
- Insulet (PODD) Announces Pricing of 6M Common Share Offering at $10.25/Share
- Insulet Corporation Announces Pricing of Public Offering
- Morning Movers 10/29: ROIAK, GIGA, HS, TBL, KDN, CATM Higher; TSPT, CPF, CYTK, KSP, FSLR, CLUB, PODD Lower
- Insulet (PODD) to Offer 5.5M Common Shares
More News related to New Coverage
- Maxim Group Initiates Coverage on Golden Green Enterprises (CHOP) with a Buy
- Hilliard Lyons Initiates Coveage on Approach Resources (AREX) with a Buy
- Wells Fargo Transfers Coverage on Intuitive Surgical (ISRG) to a Market Perform; Raises Valuation Range
- Wedbush Initiates Coverage on Coinstar (CSTR) with an Outperform
- Thomas Weisel Starts FARO Tech. (FARO) at Overweight, $24 Price Target
Boenning & Scattergood initiates coverage on Insulet (Nasdaq: PODD) with an Outperform. Price target $13.50.
To see more analyst ratings on PODD Click Here.
Insulet Corporation, a medical device company, engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes in the United States.
Related Categories
New CoverageStocks Mentioned
-0.51Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
